Brief: TScan Therapeutics, Inc. Q2 basic EPS USD -0.51
10/08/2023 12:07
Aug 10 (Reuters) - TScan Therapeutics, Inc. Q2 collaboration and license revenue USD 3.148 million. * Q2 operating expenses USD 27.758 million * Q2 income from operations USD -24.61 million * Q2 net income USD -24.045 million * Q2 basic EPS USD -0.51
Recent news on Tscan Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Broadcom, Deere & Co, Snowflake
U.S. STOCKS ON THE MOVE-FuelCell, Gold miners, NetApp
U.S. STOCKS ON THE MOVE-AEVEX, Sirius XM, PG&E
U.S. STOCKS ON THE MOVE-TScan Therapeutics, EOS Energy, Brown-Forman Corp
Brief: TScan Therapeutics - Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics - SEC Filing